Back to Portfolio


Best-in-class platform technology for the discovery of appetite modulators

EraCal is a Zurich-based company developing appetite modulators and anti-obesity medicines, based on a best-in-class platform discovery technology. Many appetite modulators are not very effective or have unwanted side effects.

EraCal Therapeutics addresses this challenge by developing a potent and highly selective appetite suppressant. Animal models have shown that their lead compound is twice as effective at reducing weight compared to current treatments on the market. 


Homepage  Linkedin Twitter